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Abstract Modern iodinated contrast media (CM) consist of
one or two tri-iodobenzene rings. They differ from each other
in the composition of the side chains, creating different mol-
ecules and thus different brand substances. After intravascular
administration, all CM are distributed rapidly into intravascu-
lar and extracellular fluids. They are eliminated solely by
glomerular filtration. In patients with normal renal function,
CMs are eliminated within 24 h. The pathophysiology of
contrast-induced nephropathy (CIN) is based on three distinct
but interacting mechanisms: medullary ischaemia, formation
of reactive oxygen species and direct tubular cell toxicity. The
contribution of each of these mechanisms to the development
of CIN in the individual patient remains unclear. CIN preven-
tion is extensively described in guidelines, such as the recently
updated guideline from the Contrast Media Safety Committee
(CMSC) of the European Society of Urogenital Radiology
(ESUR). The recent update is briefly discussed. Furthermore,
it remains unclear if volume expansion with either NaCl 0.9 %
or NaHCO3 1.4 % is superior.
Teaching points
• After intravascular injection, CM are distributed over intra-
vascular and extracellular fluids.
• CM are eliminated by glomerular filtration in patients with
normal kidney function.
• CIN pathophysiology is based on medullary ischaemia,
formation of reactive oxygen species (ROS) and tubular cell
toxicity.
• It remains unclear if volume expansion with either NaCl
0.9 % or NaHCO3 1.4 % is superior.
Keywords Contrast media . Clinical pharmacology .
Pharmacokinetics . Kidney diseases . Guidelines as topic
Introduction
Contrast-induced nephropathy (CIN) refers to acute kidney
injury (AKI) after intravenous or intra-arterial administration
of contrast media (CM). Several definitions and classifications
on AKI exist and are proposed in the nephrological literature
[1, 2] The most widely used CIN definition is from the
Contrast Media Safety Committee (CMSC) of the European
Society of Urogenital Radiology (ESUR): an increase in serum
creatinine (SC) of at least 25 % or 44 μmol/l within 3 days after
CM administration in absence of an alternative aetiology [3].
The incidence is highly dependent on renal function prior to CM
administration and additional risk factors, of which diabetes
mellitus is the most important one. Incidence varies from less
than 2 % in the general population up to 50 % in patients with
advanced kidney disease [4]. CIN is the third most common
cause of hospital acquired renal failure, with an incidence of
11 % [5]. Furthermore, CIN is associated with increased mor-
bidity and mortality within 2 years following occurrence [3, 4].
In recent years, a controversy emerged as to whether CIN
incidence is dependent on the administration route. Recently
updated guidelines state that the CIN incidence is higher after
intra-arterial administration than after intra-venous adminis-
tration [3]. This is supported by literature, for example, intra-
arterial peripheral digital subtraction angiography has shown a
CIN incidence of up to 14.3 % [6]. A recent meta-analysis
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regarding CIN incidence after contrast-enhanced computed
tomography (CT) has shown a pooled CIN incidence of
6.4 % [7]. In a group of 747 patients, who underwent 944
procedures with intra-venous CM administration, CIN inci-
dence was 2.4%. All high-risk patients received pre- and post-
hydration in accordance with current guidelines [8]. On the
other hand, a recently published study, describing 170 patients
who received both intra-arterial and intra-venous CMwithin 1
year, showed a similar CIN incidence of 14 % in the intra-
arterial group and 11.7 % in the intra-venous group. It was
concluded that CIN incidence is similar after intra-arterial and
intravenous CM administration, after adjustment for patient-
related risk factors [9].
Second, several authors question the existence of CIN.
In a 2006 published literature analysis, the authors found
only two articles on intra-venous CM administration with a
control group that received no CM. In both articles, the
incidence of significant changes in SC was not significantly
different between the group receiving intra-venous CM and
the group receiving no CM [10]. A change in SC of at least
25 % during a 5-day period occurred in more than 50 % of
patients who had not received CM [11]. The authors con-
clude that the role of CM in nephropathy may have been
overestimated. A recently published meta-analysis de-
scribes a similar incidence of acute kidney injury between
the group receiving CM and the control group [12]. In a
recently published retrospective study of over 157,000 CT
scans in over 53,000 patients, no significant difference in
acute kidney injury was found between contrast-enhanced
and non-contrast scans [13]. As a counterbalance, another
recently published retrospective study showed that CIN
does exist after intra-venous CM administration, but only
in subtypes of patients [14]. All patients who underwent CT
over a 10-year period with sufficient SC data and stable
renal function were included, 8,826 underwent non-
enhanced CT and 8,826 underwent contrast-enhanced CT.
Intra-venous low-osmolar CM proved to be a nephrotoxic
risk factor in patients with a stable estimated glomerular
filtration rate (eGFR) less than 30 ml/kg/1.73 m2, with a
trend towards significance at eGFR 30–44 ml/kg/1.73 m2.
Intra-venous low-osmolar CM were not risk factors in pa-
tients with eGFR ≥45 ml/kg/1.73 m2 [14]. CIN incidence in
the group with eGFR ≤30 ml/kg/1.73 m2 was 36.4 %,
compared with 19.4 % in the non-enhanced CT group [14].
Although randomised controlled trials with a control
group receiving no CM are widely lacking, results of these
recently published retrospective studies provide a trend that
CIN incidence has probably been overestimated in the past,
but that CIN can occur in patients with decreased kidney
function.
The following article reviews the pharmacology of CM, the
pathophysiology of CIN and discusses some preventive strat-
egies, all for iodinated CM.
Pharmacology of CM
History
The modern era of CM started back in 1953 when Vernon
Wallingford, a chemist working for the Mallinckrodt Compa-
ny in St. Louis, MO, USA, synthesised a new class of chem-
ical compounds. This molecule contained three iodine atoms
covalently bound to an aromatic ring structure, a so-called
benzoic acid derivate [15].
The compoundWallingford synthesised was called sodium
acetrizoate (Fig. 1) and was marketed as Urokon®. This was
the first ionic, high-osmolar CM and it set a new standard in
CM. Soon ‘me too’ CM were developed, such as sodium
diatrizoate (Urografin®; Schering, Berlin, Germany) in 1954
and sodium iothalamate (Conray; Mallinckrodt, St. Louis,
MO, USA) in 1963. These CM were the dominant CM
throughout the 1960s-1980s and sodium diatrizoate still re-
mains in use today for non-vascular radiology exams [16–18].
During the period in which ionic CM were introduced and
administered extensively, it became clear that the CM could
cause serious adverse effects related to the high osmolality and
ionicity of the injected fluids. Torsten Almèn, a Swedish
radiologist, realised the role of osmolality when he observed
pain during administration of CM in angiography and com-
pared it to swimming in the almost isotonic Baltic Sea with the
eyes open which does not hurt. He hypothesised that high
osmolality caused the pain and developed a chemical process
to covert high-osmolar ionic CM into low-osmolar non-ionic
CM. This resulted in the synthesis of metrizamide in 1968
(Fig. 2) [19]. Only after several pharmaceutical companies
declined Almèn’s ideas on low-osmolar CM was he able to
persuade a Norwegian pharmaceutical company, Nyegaard, to
further develop and market metrizamide (Amipaque®). In the
1970s and 1980s the second generation non-ionic CM (Fig. 3)
with increased solubility, such as iohexol (Omnipaque®; GE,
Amersham, UK), iopromide (Ultravist®; Bayer Healthcare,
Berlin, Germany), iomeprol (Iomeron®; Bracco,Milano, Italy),
ioversol (Optiray®; Mallinckrodt, St. Louis, MO, USA) and
Iobitridol (Xenetix®; Guerbet, Aulnay-sous-Bois, France),
Fig. 1 The structural formula of
sodium acetrizoate (Urokon); the
first high-osmolar and ionic
contrast agent
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were developed and introduced in patient care in the next
decade [16, 17].
Simultaneous to the development of the new low-osmolar
CM was the introduction of an ionic dimeric compound,
meglumine-sodium ioxaglate (Hexabrix®; Guerbet, Aulnay-
sous-Bois, France) in 1979. Furthermore, non-ionic dimers
were developedwhich proved to be iso-osmolar to blood. First,
the iso-osmolar iotrolan (Isovist®; Bayer Healthcare, Berlin,
Germany) was introduced in 1994 and soon after its introduc-
tion withdrawn due to a high reported number of delayed
reactions. Currently, the only non-ionic dimer (Fig. 4) on the
market is iodixanol (Visipaque®; GE, Amersham, UK)
[20–23]. Since 1995, not a single iodinated contrast medium
has been introduced which is still marketed internationally
today.
In summary, currently four types of contrast medium are
available. High-osmolar ionic monomers, low-osmolar ionic
dimers, low-osmolar non-ionic monomers and iso-osmolar
non-ionic dimers (Table 1).
Chemical composition
The tri-iodobenzene basis of sodium acetrizoate molecule
contains 84 % iodine and thus it displays excellent radio-
opaque properties. The other positions on the aromatic ring,
numbers 1, 3 and 5, are available for side chains to improve
physicochemical and pharmacokinetic properties such as sol-
ubility, osmolality, protein binding and tolerance [15–18].
The hydrophilic side chains in sodium acetrizoate are an
acid group (−COOH at position 1) and an acetamido group
(−NHCOCH3 at position 3) to enhance solubility, salt forma-
tion and to reduce protein binding, as can be seen in Fig. 1.
The –COOH group at position 1 is responsible for the ionicity,
as it forms a cation conjugated with sodium or meglumine in
solutions. Adding another acetamido group at position 5 cre-
ated sodium diatrizoate [16, 17].
In metrizamide, the first non-ionic iodinated contrast me-
dium developed by Almen and colleagues, an acetamide
(−NHCOCH3) group was placed at both positions 3 and 5
of the aromatic ring. Novel in the development of metrizamide
was adding a derivative of glucose, containing four hydroxyl
groups, at position 1 of the aromatic ring. This proved an
important step to decrease the osmolality by eliminating the
effect of positive and negative ions in the contrast solution and
retaining radio-opaque properties [16–19].
Metrizamide proved poorly soluble and thus was of limited
use in intravenous contrast administration. Soon, however,
highly soluble polycarboxylated agents (Fig. 3) followed,
such as iohexol and ioversol. The solubility in these agents
is improved by adding more carboxyl groups to the tri-
iodinated aromatic structure [16–19].
Reduction of osmolality and further increasing the number
of iodine atoms in the molecules led to the development of
dimeric non-ionic CM. These structures consist of two aro-
matic rings containing a total of six iodine atoms covalently
bound to the ring (Fig. 4). The introduction of these non-ionic
dimers proved to reduce osmolality without significantly
influencing radio-opaque quality or systemic reactions upon
administration. Generally, dimers display a higher viscosity
than monomeric CM [16, 17].
Pharmacokinetic properties
After intravenous administration, CM are distributed rapidly
into extracellular body compartments, and rapid decreases in
plasma concentrations can be measured. The plasma concen-
tration–time plot of contrast medium pharmacokinetics dis-
plays the characteristics of a classical bi-exponential model.
Several factors determine the pharmacokinetic properties
of a contrast medium. The side chains of the aromatic rings
influence solubility, osmolality, protein binding and toxicity
profile. Lipophilic side chains, for example, will lower the
solubility in water and tend to have high plasma protein
binding, whereas a carboxyl (−COOH) group can form salts
and enhance solubility and osmolality. Hydrophilic side
chains such as acetamide groups (−NHCOCH3) and
polyhydroxylated groups (containing several –OH groups)
further improve solubility in water, tolerability and are able
to reduce protein binding. The latter property is of importance
to ensure rapid glomerular filtration. Non-ionic CM generally
are very hydrophilic [16, 17].
The amount of particles in a certain volume determines the
osmolality. It takes both cell membrane penetrating particles
Fig. 2 The structural formula of metrizamide (Amipaque); the first non-
ionic contrast medium developed by Almen et al.
Fig. 3 The structural formula of iohexol (Omnipaque); an example of a
highly soluble polycarboxylated contrast medium
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and non-penetrating particles into account. Penetrating solutes
can enhance the cell volume by attracting water after passing
the cell membrane, whereas non-penetrating solutes outside
the cell will attract water from the cell. High osmolality is one
of the co-factors responsible for tolerability of CM. Ionic CM
are molecules with an electrical charge and solutions in water
contain cations such as sodium or meglumine. In general,
these solutions contain more particles per millilitre and thus
have a higher osmolality than non-ionic CM. High osmolar
CM are less tolerable than low-osmolar or iso-osmolar CM.
Fig. 4 The structural formula of
iodixanol (Visipaque); a non-
ionic dimer consisting of two
aromatic rings, each containing
three iodine atoms
Table 1 Pharmacological and pharmacokinetic parameters of iodinated CM [23]
Generic name (brand name),
year of introduction









































320 No No 290 25.4 @ 20 °C 11.4 @ 37 °C 21 120
a Approximate elimination half-life after intravenous injection in patients with normal renal function
b Iomeprol exhibits biphasic distribution with a first short period and a second longer period
c Data after intravenous infusion unknown
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Non-ionic CM do not have an electrical charge and generally
have a lower osmotic contribution than ionic CM [16, 17].
Generally, if a larger number of iodine atoms are covalently
bound in a molecule, this molecule will be more difficult to
dissolve in water. The addition of large numbers of hydrophil-
ic carboxyl groups, cation forming groups or hydroxyl groups
is needed to achieve adequate solubility in aqueous solutions
for use of the molecule as a contrast agent.
Another important physicochemical property is viscosity.
Viscosity, best described as thickness or internal friction, of a
fluid determines the infusion rate that can be achieved. Fluids
with a high viscosity will be infused over a longer period of
time compared with fluids with a low viscosity when the same
infusion system is used. After intravenous injection, fluids
with a high viscosity can influence local circulation on a larger
scale than fluids with a low viscosity, since the latter will mix
more easily with blood.
Recent data from animal studies suggest that iso-osmolar
non-ionic dimers compared with low-osmolar non-ionic
monomers significantly increase urine viscosity, lead to in-
creased kidney iodine retention and increase the formation of
vacuoles in the renal tubular epithelium of the cortex predom-
inantly in the proximal and distal tubulus [24].
After intravascular administration, CM are distributed rap-
idly over intravascular and extracellular fluids, i.e. the CM
have a short distribution half-life (t½d). Usually, the time for
the CM to distribute evenly over the fluids is several minutes,
ranging from 2 to 30 min. Plasma protein binding is approx-
imately 1-3 % [16].
CM are not metabolised in the human body, but eliminated
quickly through glomerular filtration by the kidney. The time
to clear half of the amount of contrast medium in the blood, or
elimination half-life (t½el), is approximately 1–2 h.
In patients with normal renal function approximately
100 % of the contrast medium is excreted in the first 24 h
after administration. In patients with decreased renal function
the elimination half-life can increase to 40 h or more [25].
Alternative routes of elimination, such as biliary elimination,
are slow. Haemodialysis and peritoneal dialysis are efficient
methods to remove CM from the blood [25, 26].
An overview of physicochemical and pharmacokinetic
properties can be found in Table 1.
Pathophysiology of CIN
The pathophysiology of CIN is complex and partially under-
stood. What exactly happens inside a human kidney in vivo
can only be speculated from the results of mainly animal and
laboratory studies.
Under physiological resting conditions, 25% of the cardiac
output is directed towards the kidneys. The majority is direct-
ed towards the cortex, to optimise glomerular filtration and
reabsorption of water and salts. The medullary blood flow is
low. Its function is to preserve osmotic gradients and enhance
urinary concentration [27]. Blood flow to the renal medulla is
derived from efferent arterioles of juxtamedullary glomeruli.
At the corticomedullary junction, these efferent arterioles give
rise to the so-called distal vasa recta (DVR). These DVR
gradually form a capillary bed that penetrates deep into the
inner medulla. These capillaries eventually coalesce to form
ascending vasa recta (AVR). The transformation from DVR to
capillary to AVR occurs gradually with accompanying histo-
logical changes in the composition of the vessel wall [28].
Hypoxic medullary injury plays a critical role in CIN [29].
This is caused by three different but potentially interacting
pathways: haemodynamic effects of CM, the effect of reactive
oxygen species (ROS) and free radicals and direct CM mole-
cule tubular cell toxicity [30].
Haemodynamic effects
Under physiological circumstances, regional PO2 levels of the
renal medulla can be as low as 20 mmHg [31]. The most
vulnerable part of hypoxic damage is the deeper portion of
the outer medulla that contains the metabolically active
thick ascending limbs of the loop of Henle. In this part of
the tubular system, an osmotic gradient is generated by
active reabsorption of sodium, a process that requires a
large amount of oxygen [27]. The haemodynamic response
to intra-arterial injection of contrast medium is biphasic: a
brief initial increase in renal blood flow, followed by a
prolonged decline of 10-25 % below baseline [29, 30, 33].
This predomintantly reflects a decline in cortical blood flow,
as 10 % of renal blood flow represents medullary flow [29]
Declines of outer medullary PO2 by 50-67 % after contrast
medium administration to 9-15 mmHg have been reported
[29, 32]. The mechanism for medullary hypoxia is a combi-
nation of a decline in regional microcirculatory blood flow
and increased oxygen demand of tubular cells [29, 32].
Injection of contrast medium leads to a transient increase in
renal plasma flow, glomerular filtration and urinary output
[29]. The higher the osmolality of the injected contrast medi-
um, the higher these effects are. Both by osmotic load, as by
the effect of endothelin release, more sodium has to be
reabsorbed by distal tubular cells [29, 31, 32]. This leads to
increased oxygen consumption [31, 33].
The decline in regional blood flow has been attributed to
the response of vaso-active mediators to contrast medium
administration. Basically, an imbalance occurs between vaso-
constrictive and vasodilatative mediators. Many mediators
have been related to contrast medium administration. Promi-
nent medullary vasodilatators are adenosine, dopamine, nitric
oxide (NO), atrial natriuretic peptide (ANP) and prostaglandin
E2 [27, 31, 33]. Vasconstrictors act more on the cortical
vessels, to decrease glomerular filtration [29]. Potent
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vasoconstrictors are vasopressin, angiotensin II and
endothelin [27, 31]. Potential additional participants, both
dilatative and constrictive in the pathophysiology, are: seroto-
nin, bradykinin, leukotriens, histamine and catecholamines
[33]. To what extent each mediator plays a role is unknown.
Furthermore, the distribution of receptor mediator subtypes in
the cortex and medulla may be responsible for different re-
gional haemodynamic responses [29, 33].
More insight on the medullar microvasculature response to
CM has been given by Sendeski et al. [34]. The average DVR
diameter is 12-18 μm, close to that of a red blood cell. On
isolated rat DVRs, it was shown that micro-perfusion with
Iodixanol leads to a diameter reduction of 48 %. This was
due to a decreased NO production and an increase reactivity of
DVR to angiotensin II. Addition of a free radical scavenger,
prevented Iodixanol and angiotensin-II-induced vasoconstric-
tion [34]. Additional research from the same group showed
that Iodixanol has a more pronounced vasconstrictive effect on
afferent arterioles than on efferent arterioles. Decreased NO
availability and increased superoxide concentration explained
the increased tone and reactivity of afferent arterioles [35].
Reactive oxygen species (ROS)
Free radicals are atoms or molecules that contain one or more
unpaired electrons [30]. Examples are superoxide (O2
-) and
hydroxyl radical (OH-) [32]. These molecules are changed
into water after successive reduction reactions [30]. Less
aggressive reacting molecules, such as H2O2, are called ROS
[30, 32]. Under physiological conditions, medullary tubular
ROS formation plays an important role in cellular signalling
processes, regulation of regional microcirculation and tubular
transport by its effects on NO concentration and tubular trans-
port activity [36]. Medullary hypoxia develops after contrast
medium administration, both by decreased medullary blood
flow and increased oxygen demand of tubular cells due to
increased sodium reabsorption. This leads to increased ROS
formation and oxidative stress, an imbalance between oxi-
dants and antioxidants in favour of oxidants. The mechanisms
of increased ROS formation are complex and only partially
understood [36]. Once exceeding the cellular scavenging ca-
pacities, ROS lead to the so-called ischaemia-reperfusion
injury [36]. This refers to cellular injury caused by combined
effects of hypoxia and ROS-mediated oxidative damage. The
latter affects mitochondrial and nuclear DNA, membrane
lipids and cellular proteins [36]. ROS play an important role
in altered renal microcirculation. They trigger and increase
angiotensin-II- and endothelin-I-induced vasoconstriction.
Furthermore, bioavailability of the vasodilatative NO is re-
duced by ROS [36].
Tubular cell toxicity
Direct toxic effects of CM can only be studied in vitro, for the
effect of other cell injury mechanisms such as hypoxia, can be
ruled out [37]. In general, the toxic effects of high osmolar CM
are more pronounced than the effects of low- or iso-osmolar
CM [37]. Cytoxic effects of CM on glomerular mesangial cells
include apoptotic effects, associated with elevated intracellular
ROS levels [37]. The latter shows how pathophysiological
Table 2 Summary of practical aspects of guidelines
ESUR ACR
Indications for SC measurement
prior to contrast medium
administration
- Age >70
- History of: renal disease, renal cancer,
proteinuria, diabetes mellitus,
hypertension, gout, recent nephrotoxic drugs
- Known eGFR<60
- Intra-arterial contrast medium administration
- Age >60
- History of: renal disease, renal cancer,
renal surgery, kidney transplant,
single kidney, dialysis, hypertension
requiring medical therapy,
diabetes mellitus
- Use of metformin
Interval SC measurement – contrast
medium administration
Within 7 days No universally accepted interval
Volume expansion with NaCl 0.9 % i.v. 1-1.5 ml/kg/h ≥6 h before, ≥6 h after
contrast medium administration
100 ml/h 6–12 h before, 4–12 h after
CM administration
Volume expansion with NaHCO3 1.4 % 3 ml/kg/h 1 h before, 1 ml/kg/h 6 h after
contrast medium administration
No definite results
Emergency volume expansion Start as early as possible No guidelines
Post contrast medium administration
SC measurement
Determine eGFR 48–72 h post contrast








816 Insights Imaging (2013) 4:811–820
CINmechanisms interact and enhance each other. More effects
of CM on tubular cells have been described, including redis-
tribution of membrane proteins, reduction of extracellular
Ca2+, DNA fragmentation, disruption of intercellular junc-
tions, reduced cell proliferation, apoptosis and altered mito-
chondrial function [37].
In conclusion, CIN is a consequence of medullary ischae-
mia by both increased oxygen consumption of tubular cells
and decreased perfusion. This leads to the formation of ROS,
which enhance the effect of vasoconstrictive mediators and
reduce the bioavailability of vasodilatative mediators. Further-
more, ROS formation leads to oxidative damage to tubular
cells. CM also have a direct toxic effect on tubular cells, with
increased ROS formation as a consequence. These three
interacting pathways can finally lead to tubular necrosis.
Prevention
Regarding prevention, international guidelines exist, such as
the ACR manual on contrast media [38]. Probably the most
widely used guideline on CIN prevention is the one by the
CMSC of the ESUR, which can be easily checked on-line and
has recently been updated [3, 26]. A summary on the practical
aspects of both guidelines is displayed in Table 2.
Updated CIN Guideline by the CMSC of the ESUR
After more than 10 years, the CMSC guideline on CIN was in
need of revision and the updated guideline was published very
recently [3]. The list of patient-related risk factors has been
updated and now also includes factors related to cardiovascular
instability like a low haematocrit level, periprocedural hypoten-
sion, a recent myocardial infarction(<24 h), and use of an intra-
aortic balloon pump, which can be present in many clinical
high-care patients. The procedure-related risk factors have not
changed to a great deal, but in high risk patients it is important
to use theminimal dose of low- or iso-osmolar contrast medium
necessary for a diagnostic examination. An essential, but often
forgotten, point is that alternative imaging methods should be
considered first and in high-risk patients scheduled for CT,
there is still an underuse of MRI in daily practice.
One of the major new things in the guideline is the fact that
the route of contrast medium administration is discriminative
in assessing the risk. Based on the data and reviews of intra-
venous CM administration studies, it was concluded that the
risk of CIN in intravenous CM administration is lower than the
risk of intra-arterial CM administration. In intravenous CM
administration, several studies have shown that the risk of CIN
increases if eGFR is≤45 ml/min/1.73 m2. For intra-arterial
contrast medium administration a cut-off eGFR of<60 ml/
min/1.73 m2 has been maintained.
Volume expansion is still considered the backbone of CIN
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prophylaxis, such as N-acetylcysteine (NAC). The results of
the published studies on NAC vary considerably, with most
studies finding no significant benefit [39]. In the preventive
schemes of fluid administration, intravenous is still considered
superior to oral fluid administration due to a better control of
the volume expansion. Intravenous infusion of 1.0-1.5 ml/kg/
h saline 0.9 % starting 6 h before and continuing 6 h after
contrast medium administration has proven to be an effective
prevention scheme. Another major new item in the guideline
is the fact that intravenous administration of 3 ml/kg/h sodium
bicarbonate 1.4 %, starting 1 h before and continuing at a dose
of 1 ml/kg/h for 3 h after the contrast medium administration
is an adequate alternative in elective examinations, and the
preferred schedule in emergency situations.
Volume expansion: bicarbonate versus saline
Central volume expansion leads to an increased intravascular
volume. As a consequence, renal blood flow and diuresis
increases, leading to decreased contact time of contrast medium
with renal tubular cells. Supression of the renin-angiotensin
system occurs, leading to a general renal vasodilatation [3, 4,
40]. Volume expansion is a safe procedure, with six adverse
events reported in 511 procedures (1.2 %) [8].
An ongoing controversy in intravenous hydration is whether
to use NaCl 0.9 % or NaHCO3 1.4 % intravenously. NaHCO3
1.4 % is commercially available and therefore widely used for
volume expansion. It equals NaHCO3 167 mEq/l, the closest
commercially available product to the researched NaHCO3
154 mEq/l. The hypothesis behind the possible increased pro-
tective effect of NaHCO3 is as follows: the use of NaHCO3
leads to alkalisation of renal tubular fluid; in a more alkali
environment, ROS formation is impaired [3, 40].
The first published randomised controlled trial (RCT) on this
subject by Merten et al. [41] described 119 patients undergoing
either coronary angiography (CAG), CT, diagnostic or therapeu-
tic angiography or TIPS procedure. They were randomly
assigned to receive either NaCl 154 mEq/l in 5 % dextrose
and H2O or NaHCO3 154 mEq/l in 5 % dextrose and H2O.
Both solutions were intravenously administered at 3 ml/kg/h for
1 h before CM administration and 1 ml/kg/h for 6 h after CM
administration. CIN incidence in the NaHCO3 group was 1.7 %
versus 13.6 % in the NaCl group [41]. This RCT shows con-
vincing evidence in favour of NaHCO3 hydration, but the used
hydration schedule for NaCl was rather unusual. Most hydration
schedules with NaCl, use isotonic saline (0.9 %) and a much
longer pre- and post-hydration time of up to 12 h.
The results of this RCT, triggered the performance of new
RCTs regarding NaHCO3 versus NaCl. Two trails compared
the effect of a single bolus of NaHCO3 before CAG or PCI [42,
43]. Both RCTs showed significantly less CIN in the group
treated with the NaHCO3 bolus [42, 43]. One RCT created its
ownmixture of NaHCO3with NaCl 0.45% [44]. The results of
this trial are therefore not comparable to any of the other
published RCTs. For four other RCTs, the schedule of Merten
et al. [41] was used for prior and post NaHCO3 hydration, as
described in the section above. This schedule has been com-
pared with several NaCl schedules in mainly cardiology patient
groups with different stages of renal impairment [45–48]. An-
other RCT uses the same NaHCO3 concentration, but admin-
isters 1 ml/kg/h from 6 h before till 6 h after contrast medium
administration [49]. The final RCT uses a more or less compa-
rable schedule of NaHCO3 150 mEq/l at a rate of 3 ml/kg/h for
1 h before contrast medium administration and 1.5 ml/kg/h for
4 h after CM administration [50] The results of these more or
less comparable RCTs are displayed in Table 3.
Recently an abstract has been published online describing the
results of a randomised controlled trial regarding 1 h pre-
hydration with 250 ml NaHCO3 1.4 % versus 4–12 h pre- and
post-hydration with 1,000 ml NaCl 0.9 %. CIN incidence was
3.3 % in the NaHCO3 group and 3.7 % in the NaCl 0.9 % group
[51]. This indicates that a short NaHCO3 pre-hydration schedule
can be safely used in CIN prevention, which can lead to a
reduction in hospital stay and therefore a reduction in costs [51].
From these seven more or less comparable RCTs on intra-
venous volume expansion, four show a statistically significant
difference in favour of NaHCO3. None of these RCT’s has an
outcome in favour of NaCl. Therefore, the CMSC conclusion
that pre- and post-hydration with NaHCO3 is at least equal to
NaCl, is justifiable.
Conclusions
The pharmacology of iodinated CM is simple. A quick distri-
bution within the extra-vascular space, no metabolisation and
excretion solely by glomerular filtration. The pathophysiology
of CIN has three branches that interact with each other:
haemodynamic effects, formation of ROS and tubular cell
toxicity. Prevention is extensively described in guidelines.
Recently, ESUR guidelines have been updated.
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